2KH2
Solution structure of a scFv-IL-1B complex
2KH2 の概要
| エントリーDOI | 10.2210/pdb2kh2/pdb |
| 分子名称 | Interleukin-1 beta, scFv (2 entities in total) |
| 機能のキーワード | scfv, single chain fv, il-1b, antibody, cytokine, inflammatory response, mitogen, pyrogen, secreted, cytokine-immune system complex, cytokine/immune system |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| 細胞内の位置 | Secreted: P01584 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 44789.14 |
| 構造登録者 | Wilkinson, I.C.,Hall, C.J.,Veverka, V.,Muskett, F.W.,Stephens, P.E.,Taylor, R.J.,Henry, A.J.,Carr, M.D. (登録日: 2009-03-23, 公開日: 2009-09-08, 最終更新日: 2024-10-30) |
| 主引用文献 | Wilkinson, I.C.,Hall, C.J.,Veverka, V.,Shi, J.Y.,Muskett, F.W.,Stephens, P.E.,Taylor, R.J.,Henry, A.J.,Carr, M.D. High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J.Biol.Chem., 284:31928-31935, 2009 Cited by PubMed Abstract: Monoclonal antibodies have recently started to deliver on their promise as highly specific and active drugs; however, a more effective, knowledge-based approach to the selection, design, and optimization of potential therapeutic antibodies is currently limited by the surprising lack of detailed structural information for complexes formed with target proteins. Here we show that complexes formed with minimal antigen binding single chain variable fragments (scFv) reliably reflect all the features of the binding interface present in larger Fab fragments, which are commonly used as therapeutics, and report the development of a robust, reliable, and relatively rapid approach to the determination of high resolution models for scFv-target protein complexes. This NMR spectroscopy-based approach combines experimental determination of the interaction surfaces and relative orientations of the scFv and target protein, with NMR restraint-driven, semiflexible docking of the proteins to produce a reliable and highly informative model of the complex. Experience with scFvs and Fabs targeted at a number of secreted regulatory proteins suggests that the approach will be applicable to many therapeutic antibodies targeted at proteins, and its application is illustrated for a potential therapeutic antibody targeted at the cytokine IL-1beta. The detailed structural information that can be obtained by this approach has the potential to have a major impact on the rational design and development of an increasingly important class of biological pharmaceuticals. PubMed: 19776018DOI: 10.1074/jbc.M109.025304 主引用文献が同じPDBエントリー |
| 実験手法 | SOLUTION NMR |
構造検証レポート
検証レポート(詳細版)
をダウンロード






